Knocked Out by Nasdaq

Premium

By Jennifer Friedlin

The Nasdaq has been about as unkind to genomics companies so far this year as it was kind to them in 2000. On January 23, genomics Judgment Day, the Nasdaq slashed from 202 to 76 the number of companies in its Biotechnology Index for failure to meet a handful of criteria. Among these companies were six members of the GTI: Compugen, DeCode, InforMax, Lynx Therapeutics, Rosetta Inpharmatics, and Variagenics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.